secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2026-09-04T22:26:16+00:00
Accession:  0001493152-26-041616
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos converts $2.86M debt into 11.4M shares; dilution up to 52% of prior outstanding
--------------------------------------------------------------------------------

- Twelve exchange agreements with Streeterville Capital dated Aug 31, 2026 convert $2,861,270 of note principal into up to 11,445,080 shares at avg $0.25/share.
- After exchanges, Streeterville Note balance reduced to ~$3.7M from original $8.225M (June 9, 2025).
- Pre-exchange shares 22,164,313; post-settlement 33,609,393, a ~52% increase from dilution.
- No cash proceeds; Section 3(a)(9) exemption; shares free-trading with tacked holding period to Jun 9, 2025.
- Beneficial ownership limited to 4.9%; later exchanges require sell-down of prior shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315226041616/0001493152-26-041616-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315226041616/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-041616

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer